Introduction
============

Colorectal cancer (CRC) is the third-most common cancer diagnosed in the United States in both men and woman, and the American Cancer Society estimates 134,490 new cases and 49,190 deaths in 2016 [@B1]. Despite recent improvements in cancer care and awareness, incidences are still steadily growing. Although colonoscopy has allowed for earlier detection, a better understanding of tumor biology and prognosis are still needed. Recently, advances in RNA sequencing have increased the understanding of the molecular mechanisms behind CRC. Changes in whole transcriptome profiles seem to underlie specific phenotypes. Small non-coding RNAs consist of 17-120 nucleotides, in their mature form [@B2] and play crucial roles in the development and progression of cancer. Innovative technologies have allowed researchers to focus on the role of small RNAs in disease progression which may contribute to the development of novel therapeutic targets. An increasing number of published studies have focused on miRNAs (17-22 nucleotides) [@B3], piRNAs (26-33 nucleotides) [@B4], small nucleolar RNAs (70-120 nucleotides) [@B5], and lncRNAs (\>200 nucleotides) [@B6]. Using whole genome sequencing, present studies aim to understand the functions and transcriptional regulation of miRNA genes. Piwi-interacting RNAs (piRNAs) are one of the largest classes of the small non-coding RNAs family, and have been implicated in DNA methylation and post transcriptional-mediated repression of transposable elements [@B7]. However, other hypothesized functions of piRNAs remain largely unexplored [@B8]. Similarly, limited functional information is available for long non-coding RNAs (lncRNAs) [@B9]. Likewise, small nuclear RNAs (snRNAs) in eukaryotes consist of small nucleolar RNAs (snoRNAs), which carry out the fundamental role of ribosomal (rRNA) and transfer RNA (tRNA) modification and processing [@B10]. Two classes of snoRNAs, C/D and box H/ACA snoRNAs, have been shown to differ in sequence and structure [@B10].

In the present study, we carried out in-depth data analysis to identify the transcriptomic expression "signatures" of small RNAs from benign, tumor, and metastatic tissue samples from colorectal cancer patients, using existing datasets. We thoroughly analyzed the most predominant ncRNA expression in each sample type along with signaling pathways for possible biomarker development and identification of therapeutic targets in colorectal cancer.

Materials and Methods
=====================

Samples and data assembly
-------------------------

Colorectal cancer (CRC) small RNA sequencing (eight matched patients; 8 benign, 8 tumors, and 8 metastasis) datasets (project no: PRJNA201245; GEO: GSE46622) were downloaded from the NIH bioproject [@B11]. Detailed clinical information of patients was previously mentioned by Rohr et al [@B11]. Raw files were downloaded as [s]{.ul}equence [r]{.ul}aw [a]{.ul}rchive (SRA) files that were converted to FASTQ using SRA tool Kit version 2.5.7. Data was assembled using PartekFlow^®^ software, version 5.0 (Partek, Inc., St. Louis, MO, USA). Converted FASTQ files were uploaded to the PartekFlow^®^ server and remapped to human genome hg19 (UCSC Genome Browser). Transcript abundances were determined and expression values were represented using reads per kilobases of exon model per million mapped reads (RPKM). All small RNA expression RPKM values \>1 and representing at least 10% of the samples were considered robustly expressed and used for further analysis. Expression matrices were aligned to clinical pathologic features in order to compare miRNA, piRNA, lncRNA, and snRNA levels for association with specific CRC phenotypes. Statistical analysis between benign, tumor, and metastasis groups were carried out using the non-parametric Mann-Whitney U test followed by false discovery rate (FDR) correction through the Benjamin-Hochberg method, with the default *p* value \<0.05 considered statistically significant [@B12].

Assembly of miRNA, piRNA, lncRNA and snoRNA annotations
-------------------------------------------------------

Small RNA sequencing data was trimmed and aligned to the whole human genome (hg19), and BWA-0.7.12 aligner (BWA-MEM) with a few modifications (mismatch penalty 2, gap open penalty 6, clipping penalty 4 and alignment score cutoff 15) for short read mapping [@B13]. miRNAs were annotated from miRBase version 21 (<http://www.mirbase.org/>), which contains more than 1900 high confidence miRNAs [@B14]. piRNA data was generated and annotated from piRBase (regulatoryrna.org/database/piRNA), which is manually curated with a focus on piRNA functional analysis [@B15]. lncRNAs were quantified using reference annotation LNCipedia (<http://www.lncipedia.org>) version 3.1, downloaded from all coordinates relative to the hg19 reference genome [@B16]. Total small RNA (including miRNA, piRNA, snRNA, mtRNA, snoRNA, piRNA, tRF3, tRF5, tRNA, rRNA) was annotated following download of GenCode version 21 ([www.GenCodegenes.org](http://www.GenCodegenes.org)), which provides comprehensive, up-to-date information on human small non-coding RNAs, with specific regard to small nuclear and nucleolar RNAs.

Biological processes and gene network visualization: MetaCore
-------------------------------------------------------------

To investigate biological pathway interactions of small RNA expression, we used MetaCore pathway analysis of differentially expressed genes (Thomson Reuters, New York, NY) [@B13], [@B17], to delineate functional gene networks. This was based on differentially regulated gene lists with p\<0.05 from each group (tumor vs benign, metastasis vs benign, metastasis vs tumor) as input (Data analyzed by Gene Arrays, New York, USA) to generate disease biomarkers and GO terms.

Statistical Analysis
--------------------

All data sets were subjected to paired student\'s *t* test with "*p*" value \<0.05 being considered statistically significant. Furthermore, the Benjamini and Hochberg multiple testing adjustment method was applied to all small RNA sequencing studies and pathway analysis.

Results and Discussion
======================

Analysis of miRNA sequencing of colorectal cancer tissue samples
----------------------------------------------------------------

To identify miRNA differential expression in colorectal cancer patient-matched tissue samples, data was downloaded from the GEO series accession number GSE46622. Using PartekFlow software miRNA analysis, we identified 19 miRNAs in the tumor vs benign cohort, and 38 miRNAs in the metastasis vs benign cohort, that were statistically significant. Top upregulated/downregulated miRNAs were determined in both tumor, metastasis stages (Figures [1](#F1){ref-type="fig"}A and 1B, Table [1](#T1){ref-type="table"}), and hierarchical clustering/Venn diagram was compared for each group (Figure [1](#F1){ref-type="fig"}C). Our findings were very similar to those originally published by Rohr et al [@B11], in which one of the top downregulated microRNAs was miR-1. It is downregulated during disease progression from tumor (4-fold) to metastasis (8-fold, Figure [1](#F1){ref-type="fig"}B), along with miR-145, miR-378a, miR-143 and miR-497 commonly regulated in both tumor and metastasis samples. Additionally, miR-31, miR-183, miR-135b, miR224 and miR-584 were upregulated with disease progression (Figure [1](#F1){ref-type="fig"}A, 1B and 1C). All of the miRNAs with fold change were listed in Table [1](#T1){ref-type="table"}. miR-1 downregulation is consistent with other studies that showed its downregulation in colorectal cancers [@B18]. Several other miRNAs were expressed at low levels in normal tissue, strongly upregulated in tumors, and continued to be further upregulated in late stage (metastatic) CRC. miR-31 (9.3-fold), miR-183 (7.5-fold), miR-135b (6-fold) and miR-224 (3.6-fold), were all significantly expressed in metastasis in the sequencing data, in agreement with other studies demonstrating the same expression pattern in CRC and other disease states [@B19]-[@B21]. Specifically, miR-31 expression in benign samples was negligible and increased significantly with disease progression, this data is similar to previous reports showing increased presence of miR-31 in several cancer types with metastasis [@B22].

Once miRNA gene expression was determined, we performed biological pathway analysis, using MetaCore software (previous known as GeneGo; v6.25), to identify candidate "molecular signatures." Pathway analysis on differentially expressed benign, tumor, and metastasis samples were obtained. As expected, most of the affected miRNAs were involved in cell regulation, cell proliferation, migration, and angiogenesis of colorectal cancer (Figure [2](#F2){ref-type="fig"}A). Gene ontology (Figure [2](#F2){ref-type="fig"}B) and disease by biomarkers (Figure [2](#F2){ref-type="fig"}C) clearly showed that most of the miRNAs were known to be involved in colorectal and/or other cancer types. Regulation and proliferation pathway analysis data of miRNAs in tumor vs benign and metastasis vs benign cancer samples, showed most of the miRs were involved in colon cancer and cellular migration (Figures [3](#F3){ref-type="fig"}A-3E). We further viewed the network analysis of the miRNAs that were involved in signaling pathways. We observed three major pathways were commonly affected in the tumor and metastasis groups (Figures [3](#F3){ref-type="fig"}F-3H) and only specific to the metastasis group (Figures [3](#F3){ref-type="fig"}I-3K).

Differentially expressed piRNAs in colorectal cancer tissue samples
-------------------------------------------------------------------

Piwi-interacting RNAs are the largest class of non-coding RNAs [@B23] recently shown to play important roles in cancer progression. They also represent a third class of small RNA silencers (other two classes are miRNAs and siRNAs) that form RNA-protein complexes by interacting with piwi-proteins. These are required for both epigenetic and post-transcriptional gene silencing of retrotransposons and other genetic elements in germ line cells, particularly during spermatogenesis [@B24]. We remapped aligned small RNA sequenced data with piRBase annotation and identified six piRNAs (including two piRNAs with alternative transcripts) whose expression levels were statistically significant (p\<0.05; Figure [4](#F4){ref-type="fig"}A, and group wise hierarchical clustering with Venn diagram in Figure [4](#F4){ref-type="fig"}B). Two piRNAs were commonly upregulated in both tumor and metastasis groups. Tumor vs benign group enriched only four piRNAs which piR-hsa-25447 (3-fold), piR-hsa-23992 (3-fold), and piR-hsa-1043 (2.4-fold) were upregulated and the remaining one downregulated \[piR-hsa-28876 (2.3-fold)\]. In the metastasis vs benign group, 27 piRNAs were enriched (with multiple transcripts) of which 22 were upregulated \[Top five: piR-hsa-22842 (22-fold), piR-hsa-23317 (9.5-fold), piR-hsa-26131 (6-fold) piR-hsa-23210.1 (6-fold) and piR-hsa-25447 (5.7-fold) and the remaining five downregulated \[piR-hsa-27729 (3.4-fold), piR-hsa-7193.1 (3.4-fold), piR-hsa-7193.2 (3.2-fold) piR-hsa-27729.1 (3-fold) and piR-hsa-27730.1 (2.4-fold)\] (All piRNAs were listed in the Table [2](#T2){ref-type="table"}). Recently, more attention is being focused on piRNAs in relation to biologic functions and epigenetic involvement of the biomarker for diagnosis, prognosis, and therapeutic use, which still remains largely unknown. Although piRNA detection in cancer correlates with poorer clinical outcomes suggesting a functional role [@B25], data available so far is not sufficient to entirely discriminate between a \'passenger\' role for the ectopic expression versus a \'driver\' role in the pathogenesis of these diseases [@B25]. Cancer associated piRNAs are especially upregulated in breast cancer (piR-4987, piR-20365, piR-20485, piR-20582 and piR-932) [@B26], [@B27], and gastric cancer (piR-823 and piR651) [@B28], [@B29]. In kidney cancer both upregulated piRNAs (piR-32051, piR-39894, piR-43607) and down-regulated piRNAs (piR-38756, piR-57125, piR-30924) [@B30] have been identified. piRNA down-regulation has also been observed in pancreatic cancer (piR-017061) [@B31], multiple myeloma (piR-823), and lung cancer (piR-L-163) [@B32].

Differentially expressed long non-coding RNAs in colorectal cancer tissue samples
---------------------------------------------------------------------------------

Long non-coding RNAs, larger than 200 nucleotides [@B24], are the most recent and least characterized ncRNAs. lncRNAs have tissue-specific expression and are expressed in a regulated manner correlating with distinct gene sets that influence cell function [@B33]. They are also expressed as both tumor suppressors and promoters [@B34]-[@B36]. Our small RNA sequencing data was remapped to identify differentially expressed lncRNAs in colorectal cancer samples. It revealed 18 lncRNAs in tumor vs benign, 89 in metastasis vs benign, and 15 in metastasis vs tumor groups being significantly expressed (p\<0.05). The top upregulated ones being lnc-SLC47A1-3:1, lnc-RABGGTB-1:6, lnc-RPL17-2:4 and lnc-HHIPL1-3:1 (Figure [5](#F5){ref-type="fig"}A); and the top downregulated lncRNAs being lnc-ABHD3-1:4, lnc-ABHD3-1:2, lnc-ZNF860-1:1 and lnc-PCYOX1L-2:15 (Figure [5](#F5){ref-type="fig"}B). Stage wise hierarchical clustering with Venn diagram for both tumor and metastasis groups is illustrated in Figure [5](#F5){ref-type="fig"}C along with differential expressed lncRNAs listed in the Table [3](#T3){ref-type="table"}. lncRNAs are a heterogeneous group of transcripts, with diverse mechanisms and differential expression in many diseases including tumors [@B35]. ABHD3 is an alpha/beta hydrolase protein found in a wide range of enzyme domains whose function remains unknown, and multiple transcripts of this gene were downregulated in tumor and metastasis samples in this study. Further exploration is needed to assess their function in cancer and other diseases.

Differentially expressed sn/snoRNAs, mt_rRNA, miscRNA, nonsense mediated decay and rRNAs in colorectal cancer tissue samples
----------------------------------------------------------------------------------------------------------------------------

Small nuclear RNAs, form a class of RNA molecules that localize within the nucleus of eukaryotic cells [@B24]. Their primary function is pre-mRNA processing, for which they are always associated with a set of specific proteins and the complexes are referred to as small nuclear ribonucleoproteins (snRNPs). A subclass of snRNAs called small nucleolar RNAs that localize to the nucleolus are implicated in the maturation of ribosomal and transfer RNA molecules by specific chemical modifications [@B24]. We remapped the aligned reads to the GenCode database, which contains most of the curated small RNAs. We specifically looked at sn/snoRNAs, mt_rRNA, misc_RNA, nonsense mediated decay (NMD) and rRNAs. All the mentioned sncRNAs were significantly upregulated during CRC disease progression (Figure [6](#F6){ref-type="fig"}A, and stage wise hierarchical clustering with Venn diagram in Figure [6](#F6){ref-type="fig"}C). In our investigation, nine differential expression genes were noted in the tumor vs benign group, 104 in metastasis vs benign (with multiple transcripts), and 15 in metastasis vs tumor group. This sncRNA cohort included all sn/snoRNAs, mt_rRNA, misc_RNA, NMD and rRNAs, with most belonging to sn/snoRNAs (listed in the Table [4](#T4){ref-type="table"}). Increased expression was noted during metastasis, suggesting potential biomarker use in late stage cancers. Previous studies have shown the RNU family of snRNAs to be expressed in pancreatic, colorectal and lung cancers [@B37] and decreasing after tumor removal by surgery. Recent studies have also shown that the SNHG (small nucleolar RNA host genes) family of snoRNAs plays a crucial role in cancer. For example, Zhang *et al*., showed upregulation of SNHG1 in hepatocellular carcinoma, affecting tumor suppressor genes such as p53 and others [@B38], while Zhao *et al*., showed downregulation of SNHG5 in gastric cancer [@B39]. Conversely, in our study, SNHG12 (two transcripts, 4.2-fold) and SNHG1 (3.4-fold) increased. Other snoRNAs, i.e., snoRD14 (5-fold), snoRD15B (5-fold), snoRD32A (4.7-fold) were only upregulated in the metastasis stage (Table [4](#T4){ref-type="table"}). Further validation of identified snRNAs are needed to confirm their biological functions and possible use as biomarkers.

Conclusions
===========

High-throughput sequencing technologies have effectively delineated the crucial roles of non-coding RNAs in normal cellular biology and cancer progression. We have identified several small non-coding RNAs which may be involved in the stepwise progression of normal colon tissue to cancer and subsequent metastatic disease. However, their functions are still relatively unknown. Our analysis can provide a comprehensive list of the miRNAs, piRNAs, lncRNAs and sn/snoRNAs specific to each stage with the commonly expressed genes listed in Tables [1](#T1){ref-type="table"}-[4](#T4){ref-type="table"}. Further understanding and validating will allow us to link these distinct small RNAs with the phenotypic traits seen in the evolution of colorectal cancer, thereby offering a potential for biomarker development. Likewise, further understanding of their roles in cancer signaling pathways may represent a novel target for treatment. Detailed analysis of the individual transcriptome can personalize both prognosis and intervention strategies in colorectal cancer.
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###### 

**Differential expression of miRNAs in tumor and metastasis of colorectal cancer specimens:** Top four statistically upregulated (Figure [1](#F1){ref-type="fig"}A) and downregulated (Figure [1](#F1){ref-type="fig"}B) miRNAs and dendrogram view of all miRNAs that are statistically significant (p≤0.05) in the tumor and metastatic tissue samples and associated Venn diagram (Figure [1](#F1){ref-type="fig"}C).
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![**Comparative enrichment analysis of microRNA for Pathway Maps, Gene Ontology, Disease by Biomarker, and Network Processes.** MetaCore pathway analysis of small RNA-sequencing data from the tumor and metastatic cancer samples were uploaded to MetaCore servers and most significantly affected pathways analyzed. A: Pathway Maps: Canonical pathway maps were generated, where three out of the top four pathways are involved in colorectal cancer pathogenesis (regulation of miRNAs, role of miRNAs in cell proliferation; and role of miRNAs in migration, survival and angiogenesis). B: Geno Ontology: GO processes were analyzed illustrating that gene silencing of miRNA and post transcriptional gene silencing most impacted. C: Disease status: Significantly involved miRNAs in disease were listed; most of the miRNAs were involved in adenocarcinomas. D: Comparative enrichment analysis: Differential expression of miRNAs in disease groups.](jgenv05p0016g004){#F2}

###### 

**Top regulated Pathway Maps and Network processes.** Small RNA-seq data from the tumor and metastasis cancer samples were entered into MetaCore and top regulated pathways and network processes were presented. **A to E: Regulation of miRNAs in Colorectal Cancer**: Top five highest scored pathway maps linked to colorectal cancers with involved in migration and angiogenesis. Upward thermometers have red color and indicate up‑regulated signals and downward (blue) ones indicate downregulated expression levels of the genes. **F-H: Generation of biological networks using comparison Analyze Networks (cAN) algorithm common in both Colorectal Cancer groups:** Comparison of the disease group enrichment analysis revealed three commonly affected pathways in both groups.**I-K: Generation of biological networks using Analyze Networks (AN) algorithm in metastasis Colorectal Cancer group only:** This is a variant of the shortest paths algorithm with main parameters of enrichment with enriched miRNAs prioritized based on the number of fragments of canonical pathways in the networks. Up‑regulated genes are marked with red circles; downregulated with blue circles. The \'checkerboard\' color indicates mixed expression of the gene between files or between multiple tags for the same gene.
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###### 

**Differential expression of piRNAs in colorectal cancer:** piRNA analysis revealed a total of two piRNAs statistically regulated commonly between two groups. They are (Figure [4](#F4){ref-type="fig"}A) listed as dot plots. A dendrogram view of all statistically significant piRNAs (p≤0.05) are shown as hierarchical clustering and along with a Venn diagram (Figure [4](#F4){ref-type="fig"}B).
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###### 

**Differential expression of long non-coding RNAs (lncRNAs) in colorectal cancer:** Top four upregulated lncRNA were shown in Figure [5](#F5){ref-type="fig"}A and top four downregulated lncRNAs shown in Figure [5](#F5){ref-type="fig"}B. Dendrogram view of lncRNAs that are statistically significant (p≤0.05) as a hierarchical tree with stage wise comparison along with a Venn diagram (Figure [5](#F5){ref-type="fig"}C).
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###### 

**Differential expression of sn/snoRNAs, mt_rRNA, miscRNA, nonsense mediated decay and rRNAs in colorectal cancer tissue:** small RNA-seq data was analyzed for sn/snoRNAs, mt_rRNA, miscRNA, nonsense mediated decay and rRNAs with GenCode annotation and found nine genes in tumor vs benign, 104 in metastasis vs benign and 15 in metastasis vs tumor groups. Two commonly upregulated sn/snoRNAs are shown in Figure [6](#F6){ref-type="fig"}A and hierarchical clustering is shown in Figure [6](#F6){ref-type="fig"}B with an associated Venn diagram.
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###### 

Differential expression of miRNAs in three groups.
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Differential expression of piRNAs in three groups.
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Differential expression of lncRNAs in three groups.

![](jgenv05p0016g019)

###### 

Differential expression of sn/snoRNAs in three groups.
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